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Abstract
Background: Ki67 labeling index (Ki67 LI), the percentage Ki67 immunoreactive cells, is a measure of tumor
proliferation, with important clinical relevance in breast cancer, and it is extremely important to standardize its
evaluation.
Aim: To test the efficacy of computer assisted image analysis (CAIA) applied to completely digitized slides and to
assess its feasibility in routine practice and compare the results obtained using two different Ki67 monoclonal
antibodies.
Materials and methods: 315 consecutive breast cancer routinely immunostained for Ki-67 (223 with SP6 and 92
with MM1 antibodies previously examined by an experienced pathologist, have been re-evaluated using Aperio
Scanscope Xs.
Results: Mean human Ki67 LI values were 36%± 14.% and 28% ± 18% respectively for SP6 and MM1 antibodies;
mean CAM Ki67 LI values were 31%± 19% and 22% ± 18% respectively for SP6 and MM1. Human and CAIA
evaluation are statistically highly correlated (Pearson: 0.859, p<0.0001), although human LI are systematically higher.
An interobserver variation study on CAIA performed on 84 cases showed that the correlation between the two
evaluations was linear to an excellent degree.
Discussion: Our study shows that a) CAIA can be easily adopted in routine practice, b) human and CAIA Ki67 LI
are highly correlated, although human LI are systematically higher, c) Ki67 LI using different evaluation methods
and different antibodies shows important differences in cut-off values.
Introduction
The Ki67 proliferation related antigen is detectable in
cells during all phases of the cell cycle except G0, and
the Ki-67 labelling index (LI, the percentage of cells
with nuclear immunostaining) is a measure of tumour
proliferation [1,2]. Ki67 LI in breast cancer (BC) has
been studied since its discovery in the early 1980 [3],
but only recently its evaluation has gained general clini-
cal relevance as a parameter for risk assessment in early
BC [4-8]. According to the last St Gallen International
Expert Consensus on the Primary Therapy of Early
Breast Cancer, high Ki67 LI is one of the features indi-
cating increased risk of recurrence in ER-positive,
HER2-negative BC, thus indirectly supporting the value
of adding chemotherapy to endocrine therapy in such
patients [4].
The main problems which hampered the acceptance
of Ki67 LI as a prognostic/predictive parameter are
related to the high degree of interobserver variability in
its assessment [9]. Ki67 LI values can vary as a function
of several critical factors, including human error, the
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specific antibody used.
Computer assisted image analysis can improve the
accuracy and inter-observer reproducibility of immuno-
histochemical assessments, especially when this
approach is applied to completely digitized slides [10].
The recently developed technologies to scan whole his-
tological slides in a reliable and time-effective way, may
now allow a routine use of this approach.
In the present study we evaluate the feasibility of com-
puter assisted image analysis (CAIA) on digitized slides
in a large series of consecutive BC, which have been
routinely immunostained for Ki67 using two different
antibodies (SP6 and MM1) and evaluated by an experi-
enced pathologist.
Materials and methods
Patients and samples
W er e t r i e v e dt h r e eh u n d r e df ifteen consecutive breast
cancers routinely immunostained for Ki-67 observed at
the department of Surgical Pathology of the S. Chiara
Hospital, Trento, between 2007 and 2008. The series
included 236 ductal carcinomas, 41 lobular carcinomas,
23 special histotypes and 15 distant metastases. The
age of the patients was between 30 and 90 with a
mean of 63.
The original tumours have been fixed in buffered for-
malin and embedded in paraffin. One representative tis-
sue block for each tumour was selected for routine
evaluation of estrogen and progesterone receptor, Ki67
and HER2 immunohistochemical analysis. Immunohisto-
chemical analysis for Ki67 was done using the SP6 (Lab
Vision Corporation, Fremont, CA) and MM1 (Leica Bio-
systems Newcastle, UK) antibodies in 223 and 92 cases
respectively, using automated immunostainers (Autostai-
ner 720, Lab Vision for SP2 and Bondmax, Leica Biosys-
tems for MM1).
All cases have been evaluated by an experienced
pathologist counting at least 1000 cells under oil immer-
sion in the most densely labelled areas, as evaluated at
scanning magnification. For all cases the percentage of
tumour cells with moderate/intense nuclear staining was
recorded, as the Pathologist Percentage Value (PPV).
The 315 slides were scanned using the Aperio Scan-
scope Cs (Aperio Technologies, Vista, CA) with a 20x
objective. The selection of the regions of interest (ROI)
on the virtual slides was initially done by an experienced
pathologist and a technician working together. After a
training period, the selection of the areas, in cases
where tumour cell areas were easily identifiable in the
section, was done by the technician. The proprietary
algorithm for analysis of nuclear-based immunoreactivity
(IHC nuclear algorithm, Aperio Technologies) was used
to measure staining intensity and percentage of
immunoreactive cells. For each case the algorithm pro-
vides the number of analyzed cells, the percentage of
cells with absent (0) to strong (3+) immunoreactivity.
We recorded the sum of the percentages of positive
cells as the Computer Percentage Values (CPV).
To assess how the inter-observer variability affects
CAIA results, two trained technicians analyzed the same
set of 84 virtual slides, blindly selecting the ROI. The
cases have been selected to include a balanced mixture
of low, intermediate and high Ki67 expressing cases.
Pearson’s and Spearman’s correlation tests and t-test
were used to calculate the relationships between PPV
and CPV and to evaluate interobserver variability. Statis-
tical analysis was performed by using SPSS 15.0 for
Windows (SPSS Inc., Chicago, Illinois). All tests were
two sided. The statistical significance level was chosen
at 1%.
Results
The identification of the ROI on each slide and the
nuclear count analyses (Fig. 1) could be easily done by a
technician after a brief training period. The range of
cells included in the ROI was between 652 and 306.537,
with a median value of 23.813. Cases have been subdi-
vided in three groups based on tertile distribution; cut-
offs to define tertiles varied depending on antibody used
and on evaluation methods (Tab. 1).
Mean Ki67 LI values as evaluated by the experienced
pathologist were 36% ± 14% and 28% ± 18% respectively
for SP6 and MM1 antibodies; mean CAIA Ki67 LI
values were 31%± 19% and 22% ± 18% respectively for
SP6 and MM1. Human and CAIA evaluation, for both
MAbs, are statistically highly correlated (Pearson: 0.859,
p<0.0001) (Fig. 2), although human Ki67 LI are systema-
tically higher. Data are shown in detail only for cases
immunostained with SP2, because this group, due to the
larger number of cases, allows a more reliable analysis
(Fig. 3).
The 223 cases immunoistained with SP6 have been
subdivided according to the cut-off values for tertiles as
suggested by St Gallen Consensus. The percentages of
cases assigned to the three groups (with low/intermedi-
ate/high proliferative activity according to St Gallen
Consensus) differ considerably when CAIA or human
evaluation are considered (Fig. 4).
The interobserver variation study performed on 84
cases, blinded analyzed with CAIA by two observers,
showed that the correlation between the two evaluations
was linear to an excellent degree (Spearman’sr h oa n d
Pearson’s correlation coefficient are 0.925, p<0.001 and
0.913, p<0.001, respectively) (Fig. 5). The mean Ki67 LI
for the two observers were very similar ( 21.0 ± 12.7,
and 20.5 ± 12.3, respectively). However, the number of
cells counted by the two observers are significantly
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although statistically significant (Pearson: 0.550 9,
p<0.001, Spearman 0.652, p<0.001) is scarce.
Discussion
The present study shows that Ki67 immunostainings can
be easily evaluated using computer assisted image analy-
sis (CAIA) on completely digitized slides. Human and
CAIA evaluation are strictly correlated, although CAIA
values are slightly lower compared to human evaluation.
Beside confirming the feasibility of Ki67 evaluation
using an automated approach, our results underscore a
few critical aspects for the use in clinical practice of the
Ki67 LI evaluation. First, it is not possible to apply gen-
eral cut-off values to define tumours as having a low,
intermediate or high proliferative activity: cut-off values
A

B

Figure 1 CAIA Ki67 LI evaluation. Each Ki67 immunostained slide was acquired, the regions of interest were selected by an operator (areas with
yellow contours, Fig. 1a) and CAIA generated a pseudo-colour “mark-up” image as an algorithm result (Fig. 1b).
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method of measurement (human vs automated).
Since the introduction of the first monoclonal anti-
body recognizing the Ki67 molecule, the Ki67 MAb, sev-
eral other MAbs have been produced and marketed
without proper accurate evaluation of their different
performances, which can also be remarkable [11-15]. In
our routinely stained series of BC, mean Ki67 and the
cut-off values to identify tertiles based on CAIA or
human measurements are different for the two different
antibodies used (SP6 and MM1). Although these data
derive from the analysis of two different series of conse-
cutive tumors, these results likely reflect intrinsic differ-
ences between the two antibodies, since there are no
major differences in case selection and tissue fixation
between the two series. A key factor to explain the dif-
ferent immunoreactivity between SP6 and MM1 may
be the different epitopes that are targeted: SP6 targets a
C-terminus region of Ki67 while MM1 targets an inner
region; the possible different preservation of these epi-
topes after formaldehyde fixation could explain the dif-
ferent immunoreactivity [16]. Another possible
explanation resides in the different origin of the two
antibodies, which are derived from mouse (MM1) and
rabbit (SP6). Several data suggest that rabbit antibodies
m a yi n d e e db em o r ee f f e c t i v ed i a g n o s t i ct o o l si n
histopathology [17], in keeping with our results showing
that KI67 LI obtained with rabbit SP6 MAb are con-
stantly higher than the ones obtained with the mouse
MM1 MAb.
In the present study CAIA and human evaluation,
although statistically correlated, provide different Ki67
LI values, as CAIA constantly provides lower Ki67 LI
values. The reason for this discrepancy could be related
to a bias in identification of positive cells or the selec-
tion of tumour areas to be counted. CAIA identifies
almost all cells within the selected ROI, and has a lim-
ited capacity, based on a few geometrical features, of
excluding normal stromal/inflammatory cells. Thus, in
this respect, CAIA is less accurate than human evalua-
tion. However, CAIA has the advantage of measuring a
much larger number of cells as compared to human
operator at the microscope. This large number of evalu-
ated cells reduces the error risk as compared to human
evaluation, which is necessarily based on the count a
limited number of cells, which may be not representa-
tive of the whole tumor section. Moreover human
counts suffer from a bias due to the fact that positive
cells are more easily identified and counted as they are
more prone to capture the attention of the operator as
compared to the many unstained cells.
The selection of the region of interest in tumours is
another source of possible variability. We addressed this
problem, by analyzing 84 cases in a blinded fashion by
two different observers. The number of cells counted by
the two observers, which can be assumed as an index of
the extension of the selected ROIs, were statistically dif-
ferent. However the KI67 LI obtained by the two obser-
vers, were strictly and linearly related. This highlights
the fact that CAIA is sufficiently robust to be relatively
independent from the size of the ROI.
Table 1 Tertile distribution according to human or CAIA
and antibody used
Sp6 MAb MM1 MAb
Tertiles CAIA Human CAIA Human
I ≤ 19 ≤ 30 ≤ 12 ≤ 20
II 20-37 31-42 13-24 21-40
III ≥ 38 ≥ 43 ≥ 25 ≥ 41
100%
90%
80%
70%
 Sp6 MAb
50%
60%
CAIA 
  MM1 MAb
40%
30%
20%
10%
0%
10% 0% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Human 
Figure 2 Scatterplot showing the strict association between human and CAIA evaluation for SP6 and MM1.
Fasanella et al. Diagnostic Pathology 2011, 6(Suppl 1):S7
http://www.diagnosticpathology.org/content/6/S1/S7
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racy and inter-observer reproducibility of Ki67 LI assess-
ments, especially when this approach is applied to
completely digitized slides. Our data showing different Ki67
LI values depending from methodology and type of anti-
body used suggest that it is important to standardize the
methodology for Ki67 LI evaluation and that each
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Figure 3 Distribution of Ki-67 labelling values for human and CAIA evaluation (data are show only for the 223 cases immunostained with SP6
MAb).
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Figure 4 Distribution of cases according to the cut-off values for
tertiles as suggested by St Gallen Consensus.
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Figure 5 Scatterplot showing the results of 84 readings done by
two operators A and B.
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procedure used. This may allow a higher quality of prolif-
erative data collection and enhance their use in clinical
practice.
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